非布司他治疗痛风性关节炎的有效性和安全性评价

目的 对依托考昔联合非布司他治疗痛风性关节炎的有效性和安全性进行评价。方法 急性痛风性关节炎患者197例，随机分为3组。甲组给予依托考昔和非布司他（40 mg qd）、乙组给予依托考昔和非布司他（80 mg qd），丙组给予依托考昔和别嘌醇100 mg tid，分别于治疗3周、7周、13周后观察患者关节疼痛、关节肿胀、关节受限程度、血尿酸水平与药物不良反应。结果 13周后3组治疗有效率分别为96.23%，100%，96.23%，3周时甲组降尿酸效果最好，7周与13周时乙组与丙组降尿酸效果好。乙组不良反应发生率最小。结论 依托考昔联合非布司他（80 mg qd）治疗痛风性关节炎效果好，不良反应最小。

Efficacy and Safety Evaluation of Febuxostat in the Treatment of Gouty Arthritis

OBJECTIVE To evaluate the efficacy and safety of etocoxib with febuxostat the treatment of gout arthritis. METHODS One hundred and ninety-seven patients with acute gout arthritis were randomly divided into three groups. Treated with etocoxib with febuostat (40 mg qd) to the group A, etocoxib with febuostat (80 mg qd) to the group B, and etocoxib with allopurinol 100 mg tid to the group C. After 1, 3, 7 and 13 weeks of treatment, observed the levels of joint pain, joint swelling and joint limitation, serum uric acid level and adverse drug reactions. RESULTS After 13 weeks, the effective rates of the three groups were 96.23%, 100% and 96.23%. At 3 weeks, group A had the best effect of lowering uric acid, and at 7 weeks and 13 weeks, group B and group C had a good effect of lowering uric acid. Group B had the smallest incidence of adverse drug reactions. CONCLUSION Etocoxib and febuostat (80 mg qd) have a good effect with little side effects in the treatment of gouty arthritis.